Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with controls. Teens on a GLP-1 agent also were less likely to need systemic ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...

GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked ...

Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to ...

Shares of Novo Nordisk NVO rose 9.1% on Friday after the company reportedly recorded strong early prescription trends just ...

Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, Mounjaro and Zepbound, Lilly has become the first and only drugmaker to hit a $1 ...

Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market. There are plenty of reasons to like the stock beyond this ...

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated 10.3% mean weight reduction at Week 24 with a ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...